Alemtuzumab treatment for steroid-refractory acute graft-versus-host disease leads to severe immunosuppression but not to relapse of malignant disease-Reference-Cited by-同舟云学术

Alemtuzumab treatment for steroid-refractory acute graft-versus-host disease leads to severe immunosuppression but not to relapse of malignant disease

Published:2023-11-06 Issue:1 Volume:59 Page:153-155
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Philippen Lennart,Schub Natalie,Günther Andreas,Cario Gunnar,Schrappe Martin,Repp Roland,Gramatzki Martin^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

https://www.nature.com/articles/s41409-023-02144-8.pdf

Reference13 articles.

1. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature. 2001;411:385–9.

2. Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood. 2008;112:4371–83.

3. Kato M, Kurata M, Kanda J, Kato K, Tomizawa D, Kudo K, et al. Impact of graft-versus-host disease on relapse and survival after allogeneic stem cell transplantation for pediatric leukemia. Bone Marrow Transplant. 2019;54:68–75.

4. Jagasia M, Perales MA, Schroeder MA, Ali H, Shah NN, Chen YB, et al. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood. 2020;135:1739–49.

5. Mohty M, Holler E, Jagasia M, Jenq R, Malard F, Martin P, et al. Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness. Blood. 2020;136:1903–6.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Applications of Biological Therapy for Latent Infections: Benefits and Risks;International Journal of Molecular Sciences;2024-08-24